Stocks
TScan Therapeutics, Inc.TCRX
NASDAQHealthcareBiotechnology$0.20
Price as of · delayed, not real-time
TScan Therapeutics is a clinical-stage biopharmaceutical company developing T cell receptor-engineered therapies for cancer, with a lead program targeting solid tumors. The company's pipeline includes multiplexed TCR-T cell therapies designed to overcome tumor resistance, and it is advancing toward pivotal trials. Investors track TScan for its potential in the emerging TCR-T cell therapy space and its progress in addressing unmet needs in oncology.
52W Range: $0.20-$2.43
Congressional Interest in TScan Therapeutics, Inc. (TCRX)
No congressional trades have been disclosed for TScan Therapeutics, Inc. (TCRX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TCRX?
No congressional trades found for this stock.